Lanza Claudia, Sejunaite Karolina, Steindel Charlotte, Scholz Ingo, Riepe Matthias W
Department of Psychiatry and Psychotherapy II, Ulm University, Ulm, Germany.
Brain Commun. 2020 Nov 27;2(2):fcaa206. doi: 10.1093/braincomms/fcaa206. eCollection 2020.
Alzheimer's disease and depressive disorder are frequent in old age. Both may be associated with depressed mood and cognitive impairment. Therefore, finding a strategy to clarify the diagnosis underlying subjective complaints of impaired cognition and depressed mood in older persons is of utmost interest. We conducted a cross-sectional retrospective observational clinical cohort study using patient records from 2014 to 2018. From 3758 patients, we included patients aged 60 years and older with a Mini-Mental-Status Examination score of 24 and above. Final analysis included all patients in whom Alzheimer's disease biomarker analysis was performed (cerebrospinal fluid markers of Alzheimer's disease or positron emission tomography imaging; = 179) and patients with depressive disorder in whom Alzheimer's disease was ruled out by analysis of biomarkers suggestive of Alzheimer's disease ( = 70). With case-control matching for age, education and gender, performance of patients with Alzheimer's disease was worse in acquisition, consolidation and recall of verbal information and false-positive answers. None of the results, however, sufficed to differentially diagnose individual patients with Alzheimer's disease or depressive disorder. With more severe symptoms of depression, patients with biomarker-verified Alzheimer's disease performed worse in executive testing but were not additionally impaired in verbal episodic memory performance. We conclude that distinguishing between Alzheimer's disease and depressive disorder is unreliable on clinical grounds and behavioural testing alone. Diagnosing the cause of subjective complaints about deteriorating cognitive function or depressed mood requires additional biomarker assessment, whereas cognitive assessment is needed to define appropriate targets of symptomatic treatment in patients with Alzheimer's disease and depressive disorder.
阿尔茨海默病和抑郁症在老年人群中很常见。两者都可能与情绪低落和认知障碍有关。因此,找到一种策略来明确老年人认知功能受损和情绪低落主观症状背后的诊断极具意义。我们使用2014年至2018年的患者记录进行了一项横断面回顾性观察临床队列研究。在3758名患者中,我们纳入了年龄在60岁及以上、简易精神状态检查表得分在24分及以上的患者。最终分析包括所有进行了阿尔茨海默病生物标志物分析的患者(阿尔茨海默病的脑脊液标志物或正电子发射断层扫描成像;n = 179)以及通过阿尔茨海默病提示性生物标志物分析排除了阿尔茨海默病的抑郁症患者(n = 70)。通过年龄、教育程度和性别的病例对照匹配,阿尔茨海默病患者在言语信息的获取、巩固和回忆以及假阳性回答方面表现更差。然而,没有任何结果足以对阿尔茨海默病或抑郁症个体患者进行鉴别诊断。随着抑郁症状加重,生物标志物验证的阿尔茨海默病患者在执行测试中表现更差,但在言语情景记忆表现方面没有额外受损。我们得出结论,仅基于临床依据和行为测试来区分阿尔茨海默病和抑郁症是不可靠的。诊断认知功能恶化或情绪低落主观症状的原因需要额外的生物标志物评估,而对于阿尔茨海默病和抑郁症患者,需要进行认知评估以确定对症治疗的合适靶点。